Online inquiry

IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13654MR)

This product GTTS-WQ13654MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13654MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10584MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ5764MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ11924MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MLN2045
GTTS-WQ9486MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IPH-5401
GTTS-WQ10748MR IVTScrip™ mRNA-Anti-ADAMTSL5&ALB, M-6495(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA M-6495
GTTS-WQ3060MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ5469MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDB-1
GTTS-WQ6377MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CSL654
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW